Controlled Trial Evaluating Avacopan in C3 Glomerulopathy
Status:
Active, not recruiting
Trial end date:
2021-10-25
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate the effect of avacopan treatment on renal disease
activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA
OOPD